Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact

Citations to this article

Benign T cells drive clinical skin inflammation in cutaneous T cell lymphoma
Pablo Vieyra-Garcia, … , Peter Wolf, Rachael A. Clark
Pablo Vieyra-Garcia, … , Peter Wolf, Rachael A. Clark
Published January 10, 2019
Citation Information: JCI Insight. 2019;4(1):e124233. https://doi.org/10.1172/jci.insight.124233.
View: Text | PDF
Research Article Dermatology Immunology Article has an altmetric score of 5

Benign T cells drive clinical skin inflammation in cutaneous T cell lymphoma

  • Text
  • PDF
Abstract

Psoralen plus UVA (PUVA) is an effective therapy for mycosis fungoides (MF), the skin-limited variant of cutaneous T cell lymphoma (CTCL). In low-burden patients, PUVA reduced or eradicated malignant T cells and induced clonal expansion of CD8+ T cells associated with malignant T cell depletion. High-burden patients appeared to clinically improve but large numbers of malignant T cells persisted in skin. Clinical improvement was linked to turnover of benign T cell clones but not to malignant T cell reduction. Benign T cells were associated with the Th2-recruiting chemokine CCL18 before therapy and with the Th1-recruiting chemokines CXCL9, CXCL10, and CXCL11 after therapy, suggesting a switch from Th2 to Th1. Inflammation was correlated with OX40L and CD40L gene expression; immunostaining localized these receptors to CCL18-expressing c-Kit+ dendritic cells that clustered together with CD40+OX40+ benign and CD40+CD40L+ malignant T cells, creating a proinflammatory synapse in skin. Our data suggest that visible inflammation in CTCL results from the recruitment and activation of benign T cells by c-Kit+OX40L+CD40L+ dendritic cells and that this activation may provide tumorigenic signals. Targeting c-Kit, OX40, and CD40 signaling may be novel therapeutic avenues for the treatment of MF.

Authors

Pablo Vieyra-Garcia, Jack D. Crouch, John T. O’Malley, Edward W. Seger, Chao H. Yang, Jessica E. Teague, Anna Maria Vromans, Ahmed Gehad, Thet Su Win, Zizi Yu, Elizabeth L. Lowry, Jung-Im Na, Alain H. Rook, Peter Wolf, Rachael A. Clark

×

Total citations by year

Year: 2025 2024 2023 2022 2021 2020 2019 Total
Citations: 2 4 8 5 6 6 4 35
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article in year 2024 (4)

Title and authors Publication Year
Translational analysis reveals roles for resident and recruited T cell subsets in drug hypersensitivity reactions varying with reaction type
Pranali Shah, George Romar, Artur Manukyan, Wei-Che Ko, Pei-Chen Hsieh, Gustavo Velasquez, Elisa Schunkert, Xiaopeng Fu, Indira Guleria, Roderick Bronson, Kevin Wei, Abigail Waldman, Frank Vleugels, Marilyn Liang, Anita Giobbie-Hurder, Arash Mostaghimi, Birgitta Schmidt, Victor Barrera, Ruth K. Foreman, Manuel Garber, Sherrie Divito
Journal of Clinical Investigation 2024
Role of IL-4 and IL-13 in Cutaneous T Cell Lymphoma.
Mazzetto R, Miceli P, Tartaglia J, Ciolfi C, Sernicola A, Alaibac M
2024
LAIR1 prevents excess inflammatory tissue damage in S. aureus skin infection and Cutaneous T-cell Lymphoma
Dorando HK, Mutic EC, Tomaszewski KL, Tian L, Stefanov MK, Quinn CC, Veis DJ, Wardenburg JB, Musiek AC, Mehta-Shah N, Payton JE
2024
The Tumor Microenvironment as a Therapeutic Target in Cutaneous T Cell Lymphoma
Kwantwi LB, Rosen ST, Querfeld C
Cancers 2024

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts

Posted by 6 X users
On 1 Facebook pages
Highlighted by 1 platforms
46 readers on Mendeley
See more details